Twist Bioscience (NASDAQ:TWST) Shares Gap Up – What’s Next?

Twist Bioscience Co. (NASDAQ:TWST)’s share price gapped up before the market opened on Monday . The stock had previously closed at $39.24, but opened at $42.07. Twist Bioscience shares last traded at $35.51, with a volume of 472,818 shares.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on TWST. JPMorgan Chase & Co. lowered their price objective on shares of Twist Bioscience from $40.00 to $33.00 and set an “underweight” rating on the stock in a research report on Tuesday. Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an “overweight” rating on the stock in a research note on Thursday, April 10th. The Goldman Sachs Group reduced their price objective on shares of Twist Bioscience from $55.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. Robert W. Baird dropped their target price on Twist Bioscience from $54.00 to $44.00 and set an “outperform” rating on the stock in a research report on Tuesday. Finally, Scotiabank reissued an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $50.40.

Twist Bioscience Trading Down 8.9 %

The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62. The business has a 50-day moving average price of $39.02 and a two-hundred day moving average price of $43.90. The firm has a market cap of $1.95 billion, a PE ratio of -9.69 and a beta of 2.54.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings results on Monday, May 5th. The company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.10). Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The business had revenue of $92.79 million during the quarter, compared to analyst estimates of $92.00 million. Analysts forecast that Twist Bioscience Co. will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In other news, CEO Emily M. Leproust sold 2,402 shares of the firm’s stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $40.91, for a total transaction of $98,265.82. Following the sale, the chief executive officer now owns 662,692 shares in the company, valued at $27,110,729.72. This trade represents a 0.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Patrick John Finn sold 2,058 shares of Twist Bioscience stock in a transaction on Wednesday, April 23rd. The shares were sold at an average price of $39.99, for a total value of $82,299.42. Following the completion of the sale, the chief operating officer now directly owns 265,460 shares of the company’s stock, valued at approximately $10,615,745.40. This represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 12,137 shares of company stock valued at $530,112. 3.01% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in shares of Twist Bioscience by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 5,807,183 shares of the company’s stock valued at $269,860,000 after acquiring an additional 189,791 shares during the last quarter. ARK Investment Management LLC increased its position in Twist Bioscience by 4.4% during the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock worth $260,040,000 after purchasing an additional 237,772 shares during the last quarter. Thrivent Financial for Lutherans raised its stake in Twist Bioscience by 54.6% during the fourth quarter. Thrivent Financial for Lutherans now owns 1,505,753 shares of the company’s stock worth $69,972,000 after purchasing an additional 532,040 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Twist Bioscience by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 1,374,667 shares of the company’s stock valued at $63,895,000 after purchasing an additional 6,908 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new stake in shares of Twist Bioscience during the 4th quarter valued at $56,984,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.